Sunday 18 October 2026
Export TTRX’s income statement to Excel — free account
Turn Therapeutics Inc.
TTRX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 343.5% and free cash flow fell 74.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
10.57
1.02
−8.80%
Follow TTRX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+4 more TTM periods Free account |
0.00% | 0.00% | 0.00% | (3,315.33%) | |
| (192.64%) | (52.52%) | (41.16%) | (99.59%) | ||
ROIC |
0.00% | 0.00% | (502.20%) | 0.00% | |
Return on Tangible Assets |
(420.08%) | 395.79% | (60.68%) | (507.53%) | |
Free Cash Flow per Share |
(0.07) | (0.10) | (0.14) | (0.15) | |
Free Cash Flow |
(2.03) | (2.72) | (4.06) | (4.46) | |
Capital Expenditures |
(0.21) | (0.15) | (0.17) | (0.14) | |
| Other line items | |||||
Cash ROIC |
(56.23%) | (27.82%) | (17.46%) | (26.18%) | |
Accounts Payable Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.44 | 0.80 | 1.02 | 0.51 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(4.18) | (0.28) | (0.16) | (0.08) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.06) | (0.09) | (0.13) | (0.15) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates